^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DNA repair deficiency, genomic instability and immune profiling in a phase 1 study of locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and radiotherapy.
Published date:
05/16/2018
Excerpt:
The combination of V, G and RT was well tolerated. DDR alterations were identified in a large proportion of patients and were associated with improved PFS and OS...Whereas most patients...those with higher levels of pro-inflammatory cytokines were likely to harbor DDR alterations which were associated with improved outcomes.
Secondary therapy:
gemcitabine
DOI:
10.1200/JCO.2018.36.15_suppl.4128
